Healthequity Stock Financials

HQY -  USA Stock  

USD 59.23  0.22  0.37%

Understanding current and past Healthequity Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Healthequity's financial statements are interrelated, with each one affecting the others. For example, an increase in Healthequity's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Healthequity's financials over time to get the whole picture.
Healthequity Net Income Per Employee is fairly stable at the moment as compared to the past year. Healthequity reported Net Income Per Employee of 2,609 in 2021. Average Assets is likely to rise to about 3.4 B in 2022, whereas Revenue Per Employee is likely to drop slightly above 201.2 K in 2022.
Use fundamental data analysis to validate all available fundamentals of Healthequity to find out if markets are presently mispricing the company. We were able to break down and collect data for thirty-six available reported financial drivers for Healthequity, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Healthequity financials, including its shares owned by insiders, total debt, retained earnings, as well as the relationship between the revenue and earnings per share . Given that Healthequity has a number of shares shorted of 4.14 M, we strongly advise you to confirm Healthequity regular market performance to make sure the company can sustain itself down the road. Use Healthequity to enhance returns of your portfolios. The stock experiences a normal upward fluctuation. Check odds of Healthequity to be traded at $62.19 in 90 days.
  
Refresh
With this module, you can analyze Healthequity financials for your investing period. You should be able to track the changes in Healthequity individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Healthequity is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Healthequity includes many different criteria found on its balance sheet. For example, investors should never minimize Healthequity's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Healthequity's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Healthequity.

Healthequity Cash

Chance Of Financial Distress
Less than 7
Healthequity has less than 7 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Healthequity stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Healthequity's official financial statements usually reflect Healthequity's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Healthequity. For example, before you start analyzing numbers published by Healthequity accountants, it's critical to develop an understanding of what Healthequity's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Healthequity's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Healthequity's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Healthequity's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Healthequity. Please utilize our Beneish M Score to check the likelihood of Healthequity's management to manipulate its earnings.

Healthequity Company Summary

Healthequity competes with Allscripts Hlthcare, Icad, and Cerner Corp. HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company was incorporated in 2002 and is headquartered in Draper, Utah. Healthequity operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 3688 people.
Specialization
Technology, Health Information Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP42226A107
LocationUtah; U.S.A
Business Address15 West Scenic
SectorHealthcare
IndustryHealth Information Services
BenchmarkDOW
Websitewww.healthequity.com
Phone801 727 1000
CurrencyUSD - US Dollar
You should never invest in Healthequity without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Healthequity Stock, because this is throwing your money away. Analyzing the key information contained in Healthequity's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Healthequity Key Financial Ratios

Generally speaking, Healthequity's financial ratios allow both analysts and investors to convert raw data from Healthequity's financial statements into concise, actionable information that can be used to evaluate the performance of Healthequity over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Healthequity reports annually and quarterly.

Healthequity Key Balance Sheet Accounts

201720182019202020212022 (projected)
Receivables21.6 M25.67 M70.86 M72.77 M65.49 M70.66 M
Accounts Payable2.42 M3.52 M3.98 M1.61 M1.45 M1.78 M
Total Assets369.16 M510.02 M2.56 B2.71 B3.11 B3.35 B
Current Assets265.4 M394.68 M297.3 M460.18 M351.34 M316.71 M
Assets Non Current103.76 M115.34 M2.27 B2.25 B2.76 B2.97 B
Cash and Equivalents199.47 M361.48 M191.73 M328.8 M225.41 M214.87 M
Shareholders Equity346.27 M477.08 M1.03 B1.38 B1.85 B2 B
Total Liabilities22.89 M32.94 M1.53 B1.33 B1.25 B1.35 B
Current Liabilities20.49 M29.05 M151.94 M204.7 M153.19 M165.28 M
Tax Assets1.61 M5.46 M1.68 M18 K16.2 K16.63 K

Healthequity Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Healthequity's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses94.61 M106.05 M206.08 M318.24 M286.41 M309.02 M
Consolidated Income47.36 M73.9 M39.66 M8.83 M(44.29 M)(45.45 M)
Cost of Revenue94.61 M106.05 M206.08 M318.24 M332.85 M359.13 M
Gross Profit134.92 M181.19 M325.91 M415.33 M423.71 M457.16 M
Net Income47.36 M73.9 M39.66 M8.83 M(44.29 M)(45.45 M)
Operating Expenses80.5 M103.52 M248.9 M381.32 M447.94 M483.31 M
Operating Income54.42 M77.67 M77.01 M34.01 M(24.24 M)(24.88 M)
Revenues229.53 M287.24 M531.99 M733.57 M756.56 M816.28 M
Income Tax Expense4.83 M1.92 M3.49 M(4.69 M)(22.45 M)(23.04 M)

Healthequity Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Healthequity. It measures of how well Healthequity is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Healthequity brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Healthequity had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Healthequity has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(15.84 M)(13.85 M)(32.94 M)(64.59 M)(71.62 M)(73.5 M)
Depreciation Amortization and Accretion15.95 M18.18 M55.35 M115.9 M137.19 M148.02 M
Net Cash Flow or Change in Cash and Cash Equivalents59.52 M162 M(169.75 M)137.08 M(103.39 M)(106.11 M)
Issuance Purchase of Equity Shares14.56 M22.93 M469.84 M295.35 M466.39 M503.21 M
Net Cash Flow from Financing14.56 M22.93 M1.47 B52.42 M394.86 M328.74 M
Net Cash Flow from Investing(36.75 M)25.65 M(1.74 B)(96.96 M)(639.25 M)(656.07 M)
Net Cash Flow Investment Acquisitions and Disposals(483 K)40.69 M(53.84 M)2.37 M2.13 M2.3 M
Net Cash Flow from Operations81.7 M113.42 M105.01 M181.62 M141 M117.03 M
Share Based Compensation14.31 M21.06 M39.84 M42.86 M52.75 M56.91 M

Healthequity Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Healthequity's current stock value. Our valuation model uses many indicators to compare Healthequity value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Healthequity competition to find correlations between indicators driving Healthequity's intrinsic value. More Info.
Healthequity is one of the top stocks in price to earning category among related companies. It is one of the top stocks in price to earnings to growth category among related companies . The ratio of Price to Earning to Price to Earnings To Growth for Healthequity is about  250.57 . Earnings Before Interest Taxes and Depreciation Amortization EBITDA is likely to drop to about 95.1 M in 2022. Earnings before Tax is likely to drop to about (68.5 M) in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Healthequity by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Healthequity's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Healthequity's earnings, one of the primary drivers of an investment's value.

Healthequity Systematic Risk

Healthequity's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Healthequity volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Healthequity correlated with the market. If Beta is less than 0 Healthequity generally moves in the opposite direction as compared to the market. If Healthequity Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Healthequity is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Healthequity is generally in the same direction as the market. If Beta > 1 Healthequity moves generally in the same direction as, but more than the movement of the benchmark.
.

About Healthequity Financials

What exactly are Healthequity Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Healthequity's income statement, its balance sheet, and the statement of cash flows. Potential Healthequity investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Healthequity investors may use each financial statement separately, they are all related. The changes in Healthequity's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Healthequity's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Healthequity is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Healthequity grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Healthequity May 22, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Healthequity help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Healthequity. We use our internally-developed statistical techniques to arrive at the intrinsic value of Healthequity based on widely used predictive technical indicators. In general, we focus on analyzing Healthequity Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Healthequity's daily price indicators and compare them against related drivers.
Downside Deviation2.77
Information Ratio0.1049
Maximum Drawdown10.92
Value At Risk(4.05)
Potential Upside4.72
Please check Risk vs Return Analysis. Note that the Healthequity information on this page should be used as a complementary analysis to other Healthequity's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Healthequity Stock analysis

When running Healthequity price analysis, check to measure Healthequity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Healthequity is operating at the current time. Most of Healthequity's value examination focuses on studying past and present price action to predict the probability of Healthequity's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Healthequity's price. Additionally, you may evaluate how the addition of Healthequity to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Healthequity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Healthequity. If investors know Healthequity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Healthequity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Healthequity is measured differently than its book value, which is the value of Healthequity that is recorded on the company's balance sheet. Investors also form their own opinion of Healthequity's value that differs from its market value or its book value, called intrinsic value, which is Healthequity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Healthequity's market value can be influenced by many factors that don't directly affect Healthequity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Healthequity's value and its price as these two are different measures arrived at by different means. Investors typically determine Healthequity value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Healthequity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.